On 27 March 2013, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for Commission A12-16 (benefit assessment of saxagliptin / metformin).
http://ift.tt/2t1YnFR
Τετάρτη 14 Ιουνίου 2017
Addendum to Commission A12-16 (Saxagliptin / Metformin) [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου